Programme for Studying Medicinal Products for Generalised Anxiety Disorder: Analysis of the European Medicines Agency Guideline

INTRODUCTION. Generalised anxiety disorder (GAD) is the least studied anxiety disorder, as patients present with comorbid mood disorders. Finding effective treatment methods for GAD is of the utmost importance; therefore, it is essential to develop novel medicinal products for GAD. Proper clinical programme design is key to obtaining reliable data on the effectiveness and safety of a medicinal product. Currently, the Russian Federation lacks methodological guidelines for clinical studies of these medcinal products, and there is a need for developing such guidelines.

AIM. This review aimed to assess the possibility of applying the methodological approaches described in international guidelines to Russian clinical trials to develop medicinal products for GAD.

DISCUSSION. Having analysed the main provisions of the Guideline on the clinical investigation of medicinal products indicated for generalised anxiety disorder by the European Medicines Agency (EMA), the authors of this review outlined the main stages of clinical development and the methodology for using clinical data to evaluate the safety and efficacy of medicinal products for GAD. Clinical development programmes for these medicinal products should take into account research staging and mandatory long-term safety and additive effect assessments. This review highlights aspects of selecting the design, population, and primary and secondary endpoints for a clinical trial. Particular attention is paid to the consideration of comorbidities in patients.

CONCLUSION. The provisions set forth in the EMA guideline can inform the development of national guidelines for studying medicinal products for GAD.

1. Zalutskaya NM. Generalized anxiety disorder: current theoretical models and approaches to diagnosis and therapy. Рart 1. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2014;(3):80–9 (In Russ.). EDN: TBZSND

2. Karavaeva TA, Kotsyubinskiy AP. Holistic diagnosis of borderline mental disorders. St Petersburg: Spetslit; 2017 (In Russ.). EDN: VTIXZS

3. Bandelow B, Michaelis S. Epidemiology of anxiety disorders in the 21st century. Dialogues Clin Neurosci. 2015;17(3):327–35. https://doi.org/10.31887/DCNS.2015.17.3/bbandelow

4. Lijster JM, Dierckx B, Utens EM, Verhulst FC, Zieldorff C, Dieleman GC, Legerstee JS. The age of onset of anxiety disorders. Can J Psychiatry. 2017;62(4):37–46. https://doi.org/10.1177/0706743716640757

5. Weisberg RB. Overview of generalized anxiety disorder: epidemiology, presentation, and course. J Clin Psychiatry. 2009;70 Suppl 2:4–9. PMID: 19371500

6. Stein DJ, Scott KM, de Jonge P, Kessler RC. Epidemiology of anxiety disorders: from surveys to nosology and back. Dialogues Clin Neurosci. 2017;19(2):127–36. https://doi.org/10.31887/FDCNS.2017.19.2/dstein

7. Martynikhin IA. Gender differences in the epidemiology and pathogenesis of depressive and anxiety disorders in the context effectiveness of sertraline (Zoloft). Psychiatry and Psychopharmacotherapy. 2019;21(3):52–8 (In Russ.). EDN: XBOAQX

8. Zalutskaya NM. Generalized anxiety disorder: current theoretical models and approaches to diagnosis and therapy. Part 2. V.M. Bekhterev Review of Psychiatry and Medical Psychology. 2014;(4):129–34 (In Russ.). EDN: TQUTSH

9. Maron E, Nutt D. Biological markers of generalized anxiety disorder. Dialogues Clin Neurosci. 2017;19(2):147–58. https://doi.org/10.31887/dcns.2017.19.2/dnutt

10. Bobrov AE, Fayzrakhmanova EV. Clinical features, personality and cognitive-style characteristics of patients with anxiety disorders. Russian Journal of Psychiatry. 2017;(5):50–8 (In Russ.). EDN: ZOGABN

11. Bandelow B. Current and novel psychopharmacological drugs for anxiety disorders. Adv Exp Med Biol. 2020;1191:347–65. https://doi.org/10.1007/978-981-32-9705-0_19

12. Cuijpers Р, Sijbrandij M, Koole SL, Andersson G, Beekman AT, Reynolds CF. The efficacy of psychotherapy and pharmacotherapy in treating depressive and anxiety disorders: a meta-analysis of direct comparisons. World Psychiatry. 2013;12(2):137–48. https://doi.org/10.1002/wps.20038

13. Erickson SR, Guthrie S, Vanetten-Lee M, Himle J, Hoffman J, Santos SF, et al. Severity of anxiety and work-related outcomes of patients with anxiety disorders. Depress Anxiety. 2009;26(12):1165–71. https://doi.org/10.1002/da.20624

14. Nepon J, Belik SL, Bolton J, Sareen J. The relationship between anxiety disorders and suicide attempts: findings from the National Epidemiologic Survey on Alcohol and Related Conditions. Depress Anxiety. 2010;27(9):791–8. https://doi.org/10.1002/da.20674

15. Cougle JR, Keough ME, Riccardi CJ, Sachs-Ericsson N. Anxiety disorders and suicidality in the National Comorbidity Survey-Replication. J Psychiatr Res. 2009;43(9):825–9. https://doi.org/10.1016/j.jpsychires.2008.12.004

16. Pfeiffer PN, Ganoczy D, Ilgen M, Zivin K, Valenstein M. Comorbid anxiety as a suicide risk factor among depressed veterans. Depress Anxiety. 2009;26(8):752–7. https://doi.org/10.1002/da.20583

17. Hofmeijer-Sevink MK, Batelaan NM, van Megen HJ, Penninx BW, Cath DC, van den Hout MA, van Balkom A. Clinical relevance of comorbidity in anxiety disorders: a report from the Netherlands Study of Depression and Anxiety (NESDA). J Affect Disord. 2012;137(1–3):106–12. https://doi.org/10.1016/j.jad.2011.12.008

18. Mackenzie CS, Reynolds K, Cairney J, Streiner DL, Sareen J. Disorder-specific mental health service use for mood and anxiety disorders: associations with age, sex, and psychiatric comorbidity. Depress Anxiety. 2012;29(3):234–42. https://doi.org/10.1002/da.20911